SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome
CONCLUSION: In patients with ACS and T2D, addition of empagliflozin to standard ACS therapy prior to discharge is associated with improved LA function.PMID:38456717 | DOI:10.1080/00015385.2024.2324221 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 8, 2024 Category: Cardiology Authors: Amro Sehly Albert He Abdul Rahman Ihdayhid Christine Grey Scott O'Connor Gillian Green Matthew Erickson James M Rankin P Gerry Fegan Bu B Yeap Girish Dwivedi Nick S R Lan Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
This study aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. We prospectively enrolled healthy volunteers (HVs; n = 20) and patients with CKD (n = 54) with and without diabetes mellitus. Patients with CKD were divided into two age-matched and sex-matched subgroups according to urinary albumin-creatinine ratio (uACR) levels (<300 mg/g and ≥300 mg/g). The CKD group received dapagliflozin (10 mg/day). Urine samples were collected before treatment and after 3 and 6 months of dapagliflozin. Urinary kidney injury molecule-1 (KIM-1), interleukin-1Î...
Source: Clinical Pharmacology and Therapeutics - March 7, 2024 Category: Drugs & Pharmacology Authors: Junghyun Cho Seung Whan Doo Nayoung Song Minsul Lee Haekyung Lee Hyongnae Kim Jin Seok Jeon Hyunjin Noh Soon Hyo Kwon Source Type: research
Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
This study aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. We prospectively enrolled healthy volunteers (HVs; n = 20) and patients with CKD (n = 54) with and without diabetes mellitus. Patients with CKD were divided into two age-matched and sex-matched subgroups according to urinary albumin-creatinine ratio (uACR) levels (<300 mg/g and ≥300 mg/g). The CKD group received dapagliflozin (10 mg/day). Urine samples were collected before treatment and after 3 and 6 months of dapagliflozin. Urinary kidney injury molecule-1 (KIM-1), interleukin-1Î...
Source: Clinical Pharmacology and Therapeutics - March 7, 2024 Category: Drugs & Pharmacology Authors: Junghyun Cho Seung Whan Doo Nayoung Song Minsul Lee Haekyung Lee Hyongnae Kim Jin Seok Jeon Hyunjin Noh Soon Hyo Kwon Source Type: research
Prolonged postoperative euglycemic diabetic ketoacidosis in a lung transplant recipient with preoperative SGLT2 inhibitor use
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first approved by the Food& Drug Administration (FDA) in 2013 as a therapy to improve glycemic control in patients with type 2 diabetes mellitus (T2DM)1. With recent evidence suggesting decreased risk of death from cardiovascular causes as well as cardio- and renal-protective effects,2-10 the indications for SGLT2 inhibitor use have expanded to include patients with cardiovascular disease, systolic and diastolic heart failure, chronic kidney disease,11,12 as well as patients hospitalized for acute de novo or decompensated chronic heart failure, regardless of ejection f...
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 7, 2024 Category: Anesthesiology Authors: Christine H. Choi, Shivani Singh, Albert T. Cheung, Matthew Vanneman, Jai Madhok Tags: Case Report Source Type: research
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
ConclusionEmpagliflozin can have cardioprotective benefits in subjects without HF. Further studies are required to determine the effect of Empagliflozin in non-HF patients.Trial registrationThe original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials.www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - March 7, 2024 Category: Endocrinology Source Type: research
Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies
ConclusionsCompared with oGLDs, SGLT2 inhibitors reduced the risk of suffering AKI and AKI hospitalization in the real-world setting. Vigilance to the occurrence of AKI should not be an obstacle to discourage clinicians from prescribing SGLT2 inhibitors. (Source: Acta Diabetologica)
Source: Acta Diabetologica - March 5, 2024 Category: Endocrinology Source Type: research
Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
CONCLUSION: The study suggests that the use of SGLT2 inhibitors, alone or in combination with Entresto, may be effective in reducing the risk of ASCVD and its associated adverse outcomes in patients with diabetes and heart failure. This finding has important implications for the management of these conditions.PMID:38438119 | DOI:10.1177/10742484241233872 (Source: Atherosclerosis)
Source: Atherosclerosis - March 4, 2024 Category: Cardiology Authors: Ya-Wen Lin Chun-Hsiang Lin Cheng-Li Lin Che-Huei Lin Ming-Hung Lin Source Type: research
Investigational new drugs for the treatment of chronic renal failure: an overview of the literature
Expert Opin Investig Drugs. 2024 Mar 1. doi: 10.1080/13543784.2024.2326624. Online ahead of print.ABSTRACTINTRODUCTION: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease.The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.AREAS COVERED: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained f...
Source: Expert Opinion on Investigational Drugs - March 2, 2024 Category: Drugs & Pharmacology Authors: Chiara Terzo Guido Gembillo Valeria Cernaro Elisa Longhitano Vincenzo Calabrese Chiara Casuscelli Luigi Peritore Domenico Santoro Source Type: research
